Compounded Tirzepatide: Cost, Safety, and Best Providers (2026)

Last updated: November 2026 · Written by Ash at ClearMetabolic

I have been on Mounjaro (brand-name tirzepatide) for well over a year, and I track my results with regular DEXA scans. So I have firsthand experience with this molecule. For most of 2023 and 2024, compounded tirzepatide was the cheap way in, because the FDA listed tirzepatide in shortage and that let pharmacies make copies. That window is closed. The FDA declared the shortage resolved in October 2024 (reaffirmed in December 2024), and the grace periods for compounders ended on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities, per the FDA.

The price gap that made compounding attractive has also shrunk. Lilly now sells the brand Zepbound KwikPen self-pay at $299/mo (2.5 mg), $399/mo (5 mg), and $449/mo (7.5 mg to 15 mg, with a refill within 45 days). Its savings card lists Mounjaro as low as $499 for a 1-month fill when commercial insurance does not cover it (both checked Nov 4, 2026). This page covers what compounded tirzepatide is, its legal status today, what it costs, and the safety questions to ask if a provider still offers it.

Quick Facts

How It Works

Tirzepatide is a dual GIP/GLP-1 receptor agonist. Unlike semaglutide (Ozempic, Wegovy), which only targets the GLP-1 receptor, tirzepatide activates two receptors at once: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide).

Here is what each receptor does:

GLP-1 activation slows gastric emptying, reduces appetite signals in the brain, and improves insulin sensitivity. This is the same mechanism that semaglutide uses.

GIP activation adds a second pathway. GIP receptors are involved in fat metabolism, energy balance, and additional appetite regulation. The dual mechanism is what most researchers believe explains why tirzepatide produces about 47% more weight loss than semaglutide in the head-to-head trial (20.2% vs 13.7% in SURMOUNT-5).

Think of it as having two separate brake pedals for hunger and fat storage, both pressed at the same time. The combined effect is stronger than either one alone.

Compounded tirzepatide is meant to contain the same molecule as Mounjaro and Zepbound, but the FDA does not review compounded products for safety, effectiveness, or quality. Eli Lilly manufactures the brand-name versions. The pharmacology of pure tirzepatide is identical. Whether a given vial contains pure tirzepatide at the labeled strength is the open question.

How Compounding Works

Compounding pharmacies make customized medications. During a declared shortage, federal law also lets them make copies of an approved drug. When Eli Lilly could not keep up with demand for Mounjaro and Zepbound, the FDA placed tirzepatide on its official shortage list, and that is what opened the door to mass compounding in 2023 and 2024.

503A vs 503B

503A pharmacies compound medications based on individual patient prescriptions. They are regulated mainly by state boards of pharmacy. They do not have to follow FDA cGMP (current Good Manufacturing Practices) and do not undergo routine FDA inspections.

503B outsourcing facilities are registered with the FDA, follow cGMP, and are inspected. They can only compound from bulk tirzepatide when it is on FDA’s shortage list or the 503B bulks list. FDA says tirzepatide is on neither, so with their grace period over on March 19, 2025, 503B facilities are no longer a legal source for tirzepatide copies.

Legal Status in 2026

• October 2, 2024: FDA declared the tirzepatide shortage resolved. It reaffirmed that decision on December 19, 2024 after re-review.
• February 18, 2025: Grace period ended for 503A pharmacies.
• March 19, 2025: Grace period ended for 503B outsourcing facilities.
• March 5, 2025: A federal court in Texas denied the compounders’ request for a preliminary injunction against the FDA decision.

Today a 503A pharmacy generally may not make an essential copy of Zepbound or Mounjaro. A prescriber can document a significant difference for a specific patient, which changes the analysis. FDA says a product that adds another ingredient, such as vitamin B12, can still count as an essential copy when the amounts are within 10% of commercial strengths.

If a provider is still selling you compounded tirzepatide, ask them which legal pathway they rely on and what clinical reason is documented for you. A vague answer is a red flag.

Typical Dosing

Compounded tirzepatide is usually prescribed on the same dose escalation as brand-name Zepbound. Per the Zepbound label, you start at 2.5 mg weekly for 4 weeks and increase in 2.5 mg steps after at least 4 weeks on each dose. The label lists 5 mg, 10 mg or 15 mg as maintenance doses, and 15 mg is the maximum.

From my own experience on Mounjaro, the 5 mg dose was where I first noticed a real shift in appetite. I am currently on a higher dose and track my body composition with DEXA scans every few months. The weight loss has been consistent, but I also prioritize strength training and protein intake to preserve lean mass. The medication handles appetite. You still have to handle the rest.

Not everyone needs to go to 15 mg. Your prescriber should choose the dose based on your response and side effects. Do not raise your dose or speed up the schedule on your own.

Two label warnings matter here. Tirzepatide is not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. It can also make birth control pills less reliable, so the label advises switching to a non-oral method or adding a barrier method for 4 weeks after starting and after each dose increase. Stop it if you become pregnant and talk to your prescriber.

What It Costs in 2026

Here is what three programs listed for compounded tirzepatide on their own pages on November 4, 2026. Prices change often and some programs bill several months up front, so confirm what you will pay at your maintenance dose. Our 2026 GLP-1 Cash-Pay Pricing Index tracks more programs.

• Yucca Health: $258/mo month to month (source)
• Ivim Health: medication from $117/mo plus a $74.99/mo membership, so about $192/mo (source)
• MEDVi: its landing page lists tirzepatide at both $166/mo and $199/mo, so confirm at checkout (source)

Compare that with brand-name self-pay prices from Lilly (checked Nov 4, 2026):

At these prices, compounded tirzepatide saves roughly $40 to $280 a month versus brand Zepbound self-pay, depending on dose and program. In my view that gap is often too small to justify an unapproved product with an uncertain legal footing. Our Zepbound cost breakdown and Mounjaro cost breakdown cover savings cards and insurance routes.

For a full breakdown of affordable GLP-1 options, see our cheapest GLP-1 online guide.

Safety Considerations

Compounded tirzepatide uses the same active molecule as Mounjaro and Zepbound. But the manufacturing process is different, and that has safety implications.

Quality Varies Between Pharmacies

The biggest safety variable is the pharmacy producing your medication. Since 503B facilities can no longer legally make tirzepatide copies, anything you get today comes from a 503A pharmacy regulated mainly by its state board, with far less oversight than Eli Lilly’s plants.

FDA does not review compounded drugs for safety, effectiveness or quality before they are sold. As of May 31, 2026, FDA had received more than 730 adverse event reports tied to compounded tirzepatide, and it notes these are likely underreported.

What to Look For

Before starting compounded tirzepatide, ask your provider:

• Which pharmacy makes it, and under what legal pathway? Get the pharmacy name and license, and ask why your prescription qualifies for compounding now that the shortage is over.
• Do they provide certificates of analysis? Reputable compounders test each batch for potency, sterility, and endotoxins. You should be able to see these results.
• Has the pharmacy received FDA warning letters? You can search the FDA warning letter database by pharmacy name.
• Does the provider require a medical evaluation? Any legitimate program requires a prescriber to review your medical history before prescribing. No prescription means no oversight.

The Semaglutide Sodium Parallel

FDA has said semaglutide sodium and semaglutide acetate are different active ingredients from the approved drug. Ask the same question about tirzepatide. Make sure your provider can confirm they are using the same form of tirzepatide as the FDA-approved product. Ask directly if you are unsure.

Common Side Effects

The expected side effects of compounded tirzepatide are those of brand-name Zepbound and Mounjaro. In the Zepbound weight-loss trials, the label reports nausea in 25% to 29% of patients across doses (vs 8% on placebo), diarrhea in 19% to 23%, constipation in 11% to 17% and vomiting in 8% to 13%. Here is what to expect:

• Nausea is the most common side effect. It typically peaks during the first week or two at each new dose level and improves as your body adjusts. Eating smaller, less greasy meals helps significantly.
• Diarrhea is common early in treatment, especially after dose increases.
• Constipation affects some people. Staying hydrated and increasing fiber intake usually manages it.
• Decreased appetite is the therapeutic effect, but it can feel aggressive at first. In my first few weeks on Mounjaro, I had to remind myself to eat.
• Injection site reactions (redness, minor itching) are usually mild and short-lived.
• Fatigue and headaches are reported by some people, particularly at higher doses.
• Vomiting rises with dose, from 8% at 5 mg to 13% at 15 mg in the Zepbound trials.

Serious side effects are rare. They include pancreatitis, gallbladder issues, and a boxed warning about thyroid C-cell tumors seen in rodent studies. The same warnings apply to brand-name Mounjaro. Dosing errors are an added risk with compounded vials, since you measure each dose yourself and concentrations vary between pharmacies. My tirzepatide dosage chart in units shows how the same mg dose changes with vial strength.

For a detailed breakdown of what to expect, read our GLP-1 side effects guide.

Compounded Tirzepatide vs Brand-Name Mounjaro

The molecule is the same. The differences are in manufacturing, delivery format, and cost.

Brand-name Mounjaro is made by Eli Lilly in FDA-approved manufacturing facilities. Its label lists single-dose pens, single-dose vials, multi-dose vials and KwikPens. It is backed by the SURPASS diabetes trials, and the savings card lists it as low as $499/month when insurance does not cover it. Lilly sells the Zepbound KwikPen self-pay for $299 to $449/month.

Compounded tirzepatide is produced by compounding pharmacies. It typically comes in multi-dose vials, which means you draw up your own dose with a syringe. The programs we checked listed about $166 to $258 per month. The trade-off is doing more of the work yourself (measuring doses, storing vials properly), relying on the compounding pharmacy’s quality standards rather than Eli Lilly’s, and an uncertain legal footing since the shortage ended.

For a deep comparison, see our compounded vs brand-name GLP-1 guide. And for a broader comparison of the two major GLP-1 molecules, check out our Mounjaro vs Ozempic breakdown.

Frequently Asked Questions

Is compounded tirzepatide the same as Mounjaro?

Compounded tirzepatide contains the same active ingredient as Mounjaro. The molecule and mechanism of action are identical. The difference is manufacturing. Eli Lilly produces Mounjaro in FDA-approved facilities with rigorous manufacturing controls. Compounded tirzepatide is now made mainly by state-regulated 503A pharmacies, and the FDA does not test or approve it. The SURMOUNT clinical trials were run with the Eli Lilly product. Compounded versions have not been studied in clinical trials.

Is compounded tirzepatide still legal?

Only in narrow cases. The FDA declared the tirzepatide shortage over in October 2024, and the grace periods ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities. A 503A pharmacy can still compound it for an individual patient when a prescriber documents a clinical need the approved product cannot meet. Routine copies sold as a cheaper Zepbound are not permitted.

What happens if I stop taking compounded tirzepatide?

Weight regain is common after stopping any GLP-1 medication. In the SURMOUNT-4 trial, people lost 20.9% of their weight over a 36-week lead-in. Those switched to placebo then regained 14.0% over the next 52 weeks, while those who stayed on tirzepatide lost another 5.5%. This is why most prescribers treat tirzepatide as a long-term medication. Your provider should discuss a maintenance strategy with you. Some patients stay on a lower maintenance dose long-term. Others work toward a gradual taper with close monitoring.

Can I switch from compounded semaglutide to compounded tirzepatide?

Yes. Many people switch, especially if they have plateaued on semaglutide and want to try the dual-action mechanism. The tirzepatide label starting dose is 2.5 mg, and prescribers usually start there regardless of your semaglutide dose. The two drugs work on different receptor profiles, and your body needs time to adjust. Discuss the transition timeline with your prescriber.

Is compounded tirzepatide safe long-term?

Long-term safety data comes primarily from the SURMOUNT and SURPASS clinical trials conducted with Eli Lilly’s brand-name product. SURMOUNT-1 ran 72 weeks, and the SURPASS-CVOT heart outcomes trial followed people for a median of about 4 years. GI side effects were the most common problem. Compounded products have no long-term safety data of their own, and quality depends on the pharmacy. Since the shortage ended, there is also no stable legal basis for routine compounded supply, so I would not plan on it as a long-term option. Brand Zepbound self-pay ($299 to $449/month through LillyDirect) is the more durable path for most cash-pay patients. Discuss your situation with your prescriber.

What we checked

This AI-assisted public-source desk check reviewed FDA compounding policy and safety pages, the Zepbound and Mounjaro prescribing information, Lilly’s Zepbound and Mounjaro savings pages, the SURMOUNT-1, SURMOUNT-4 and SURMOUNT-5 trial abstracts, and the pricing pages of Yucca Health, Ivim Health and MEDVi on November 4, 2026. This is not a clinical review and it is not medical advice. Prices and policies change, so confirm them with the provider or your prescriber before you act.